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ABSTRACT Vitiligo is a common dermatosis occurring with 
a frequency of about 0.2-4.0% in world population. The 
main skin symptom of disease are white patches appearing 
as a result of destruction or dysfunction of pigment cells 
(melanocytes). Melanocytes are localized not only in epi-
dermis and bulge region of hair follicle, but also in inner ear 
and eyeball structures, and therefore vitiligo may coexists 
with auditory and visual disorders. The most frequent audi-
tory and visual disturbances occurring in vitiligo patients 
are discussed in this article.
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INTRodUCTIoN
Vitiligo is a systemic idiopathic disease character-
ized by the presence of sharply demarcated, discol-
ored spots caused by epidermal melanocyte loss or 
damage. This disease affects all races equally regard-
less of sex, with an incidence of 1% to 2%. The first de-
scriptions of the disease are found in ancient Indian 
guides, the Old Testament, and the Koran. Many types 
of vitiligo have been identified: localized, including 
focal and segmental, and generalized, including ac-
rofacial, vulgaris, and universal (1,2). The mechanism 
underlying the spots in vitiligo is not completely un-
derstood, although many theories of the disease etiol-
ogy have been postulated. The most popular of these 
include autoimmune, auto-cytotoxic, and neurogen-
ic mechanisms. The autoimmune theory is based on 
the coexistence of vitiligo with autoimmune diseases, 
often preceded by the signs of Sutton disease, and 
skin melanoma. In 1% to 3% of patients with mela-
noma, foci of hypopigmentation, depigmentation, or 
discoloration develop around halo nevi (3). The latest 
theories involve viral apoptotic, adhesion, and multi-
factorial disorders. 
A number of studies have explored the genes 
responsible for the development of vitiligo, includ-
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ing acetylcholinesterase, major histocompatibility 
complex, chloramphenicol transferase, cytotoxic T-
lymphocyte associated protein 4, catechol-O-meth-
yltransferase, estrogen receptor, guanosine triphos-
phate cyclohydrolase I, mannose binding lectin 2, 
protein tyrosine phosphatase non-receptor type 22, 
and vitamin D3 receptor (4). In patients with vitiligo 
and other autoimmune disorders, Jin et al. (5) located 
the NALP1 gene on the short arm of chromosome 7, 
which encodes a protein rich in leucine, a primary 
regulator of the immune system. The hypothesis re-
lating vitiligo to neurogenic mechanisms originated 
from observations of segmental vitiligo in areas 
designated by the dermatomes, and in association 
with adrenergic orthostasis or altered metabolism of 
acetylcholine and adrenergic neurotransmitters. The 
autoimmune and neurogenic theories are also sup-
ported by the presence of the Koebner phenomenon 
in generalized vitiligo (6, 7). Twenty-four hours after 
mechanical injury, non-specific migration of melano-
cytes occurs. The auto-cytotoxic hypothesis is based 
on the observation that phenol and some of its de-
rivatives are toxic to melanocytes, and can produce 
a chemical leucoderma. Tyrosinase, a key enzyme 
involved in melanin biosynthesis from phenol and 
some of its precursors, can produce free radicals and 
destroy melanocytes (8). 
A cytomegalovirus genome has been identified 
in the epidermal cells of patients with vitiligo (9). 
Patients with hepatitis C viral infection, acquired im-
mune deficiency syndrome, and human immunode-
ficiency virus carriers have an increased incidence of 
vitiligo (10-14). The hypothesis assumes that apop-
totic destruction of melanocytes is the mechanism 
of programmed cell death due to weakening of the 
protective signaling pathway, SCF (ckit) MIFT/Bcl2. 
The apoptotic process of melanocytes is exacerbated 
by the weakening of the expression of the gene en-
coding Bcl-2.
Normal interactions between melanocytes and 
the basement membrane require alpha-beta 1 integ-
rin. Interactions between melanocytes and keratino-
cytes occur through the actions of beta-catenin and 
cadherin (14). Repetitive bending of joints with unal-
tered skin in patients with vitiligo results in peeling 
and transepidermal elimination of melanocytes. This 
theory also explains the occurrence of positive Koeb-
ner symptoms in the active form of the disease (15). 
The multifactorial theory assumes that vitiligo oc-
curs primarily in genetically predisposed patients ex-
posed to a variety of adverse environmental factors. 
The etiology of vitiligo, unfortunately, remains un-
clear, and the disease has many clinical forms. Accord-
ing to the latest multifactorial theory, exogenous or 
endogenous phenols that are a competitive substrate 
for tyrosine are present in the microenvironment of 
pigment cells. Due to an imbalance in reduction and 
oxidation, competitive substrates are transformed 
into reactive quinones. Tyrosinase metabolizes qui-
nones to products that may represent new antigens. 
The newly formed antigens are presented by Langer-
hans cells in the regional lymph nodes, which leads to 
cytotoxic T cell proliferation. Finally, cytotoxic T lym-
phocytes and macrophages migrate into the skin and 
destroy melanocytes (16-18). 
The diagnosis of vitiligo is based on clinical pre-
sentation and is generally quite easy. Secondary 
studies for the diagnosis of discrete changes are 
performed by Wood’s lamp examination. The Wood’s 
lamp highlights the contrast between the properly 
colored skin and the vitiligo patch. Although vitiligo 
is not directly life-threatening, this disease can be a 
source of serious psychological problems and lead to 
social isolation (19). 
Vitiligo coexists with autoimmune diseases and 
visual and auditory disorders. In patients with vitiligo, 
discoloration of the eyelids and loss of eyelashes and 
eyebrows are frequently observed. Moreover, eye 
uveitis and, less frequently, discoloration of the iris, 
atrophy of the retinal pigment epithelium (RPE), and 
other retinal disorders, such as discoloration and/or 
increased pigmentation of the eye fundus, are ob-
served in patients with vitiligo. Vitiligo is also associ-
ated with auditory and balance disturbances (20). 
AUdIToRy mANIfeSTATIoNS of VITIlIgo 
The target tissues for the distribution of melano-
cytes are not only the epidermis and hair, but also the 
mucosa of the ear, eye, and mesencephalon (21). In 
the ear, melanocytes are located in the stria vascu-
laris as intermediate cells, where they modulate the 
function of Na+/K+ -ATPase and potassium channels, 
which are essential for creating the endocochlear 
electrical potential (22). The electrical activity of cili-
ary cells in the labyrinth is closely connected with 
their physiological ability to send afferent informa-
tion to brain areas involved in auditory and balance 
functions. 
Opinions vary on hearing loss associated with mela-
nocyte destruction. Lin et al. (23), analyzing 1258 adults, 
suggested an association between darker skin and bet-
ter hearing on the basis of subjective hearing tests. Be-
cause skin pigmentation is the marker of melanocyte 
function, it is reasonable that vitiligo may be associated 
with disturbances of the inner ear (which contains me-
lanocytes). Moreover, destruction of the epithelium is 
often coexistent in the inner ear and retina (24). 
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Several studies report impaired hearing follow-
ing disruption of melanin synthesis, melanosome 
structure, or their distribution (25). None of these 
studies, however, have examined the site of dam-
age that leads to hearing impairment, which can be 
the cochlea as well as the upper part of the auditory 
system, as seen in retinitis pigmentosa coupled with 
axonal polyneuritis followed by hearing loss (26). Me-
lanocytes are also distributed in the mesencephalon, 
which is a part of the hearing pathway. 
Ardic et al. (27) noted lower pure tone thresholds 
at higher sound frequencies (from 4000 – 16,000 Hz) 
in patients with vitiligo. Based on their observations, 
as well as the fact that social and environmental dam-
age affects hearing at the same sound frequencies, 
the authors suggested a preventive role of melano-
cytes (and melanin-containing cellular elements) for 
the sensitive inner ear cells. Sensorineural hypoacusis 
was reported also by Sharma et al. (28) in ~10% pa-
tients with vitiligo, but the conductive type of hear-
ing loss was detected in 8% of this group. Aydogan et 
al. (29) observed that patients with vitiligo have dis-
turbances in the upper part of auditory pathway, in 
cranial nerve VIII, and above the level of the cochlear 
nuclei in the pons. The frequency of hypoacusis was 
similar to that in previous reports and affected ~14% 
of 57 tested patients. Among Korean patients with 
vitiligo, hearing loss was confirmed to be connected 
with cochlear damage as objective electrocochleog-
raphy revealed increases in summation and action 
potentials of auditory cells in the labyrinth (30). The 
use of otoacoustic emissions seemed to confirm the 
pathology of the cochlear cells, especially at 4000 Hz 
(31). Moreover, successful cochlear implantation in 
patients with auditory symptoms concurrent with au-
toimmune destruction of melanocytes might be the 
evidence for cochlear localization of hearing injury 
related to vitiligo (32). 
Some reports, however, do not support a con-
nection between hearing loss and vitiligo. Escalante-
Ugalde et al. (33), Ozuer et al. (34), and Al-Mutairi et 
al. (35) observed no correlation between hypoacusis 
and vitiligo, even in a large group of 197 patients. Go-
pal et al. (36) suggested that the hearing loss could 
result from other diseases coexisting with vitiligo, 
such as diabetes mellitus and hypothyroidism. In fact, 
as vitiligo is reported to be of systemic origin, auto-
immune-associated diseases could be responsible 
for the observed hypoacusis. Akay et al. (37) reported 
that 55% of patients with vitiligo have autoimmune 
diseases. Abad et al. (38) emphasized the role of self-
antigens originating from melanocytes, but a search 
for targeted melanocytic proteins in patients with 
multisystemic autoimmune diseases of tissues con-
taining melanin in the eye, inner ear, meninges, and 
skin was unsuccessful. 
Several issues remain to be solved regarding vitili-
go and the associated impairment of sensory organs. 
First, there is a clear connection between hearing loss 
and melanocyte disease; second, the localization of 
the auditory pathway injury; and third, the coinci-
dence of auditory and balance system destruction in 
some clinical cases of vitiligo. 
oCUlAR mANIfeSTATIoNS of VITIlIgo 
Depigmentation of the eyelid and poliosis of the 
eyebrows and eyelashes are often observed in vitiligo 
(39). In addition to the skin, melanocytes are found in 
the leptomeninges, retinal pigment epithelium (RPE), 
the uveal tract, and the inner ear. Typically, melano-
cyte abnormalities in the eyes and ears are asymp-
tomatic and not observed by physicians, but their in-
volvement in vitiligo is well established and in some 
cases can be related to severe ocular diseases. There 
are two populations of pigment-bearing cells in the 
eye: the uveal melanocytes, which are morphologi-
cally similar to dermal melanocytes, and the RPE (40). 
Melanocytes present in the choroid are responsible 
for constitutive eye pigmentation and protection 
against ultraviolet (UV) radiation. These cells are im-
portant for the degradation of toxic factors (41). The 
association of vitiligo with inflammation of the uveal 
tract is well established. Clinical manifestations of 
acute uveitis in patients with vitiligo were observed 
in 8% of 112 patients (42). Biswas et al. reported the 
symptoms of uveitis in only 5% of a group of 100 pa-
tients (43). Wagoner et al. reported a 4.8% incidence 
of uveitis in a group of 223 patients with vitiligo and 
5.4% incidence of cutaneous depigmentation in a 
group of 129 patients with uveitis of an unknown 
cause (44). 
Vitiligo is associated with pigmentary changes 
in the fundus of the eye. The RPE is formed by a dis-
tinct type of melanocytes as the outermost layer of 
the retina. These melanocytes are involved in the 
metabolism of retinoids and rod outer segments, and 
play a major role in vision (41). Although melanocyte 
abnormalities in the fundus of the eye are usually as-
ymptomatic, they occur frequently. Wagoner et al., in 
a study of 223 patients with vitiligo, reported chorio-
retinal scars and RPE hypopigmentation in 30% of the 
patients or RPE atrophy in 27% of the patients (44). 
Cowan et al. detected some degree of fundal pig-
ment disturbance in 40% of 156 patients with vitiligo 
(45). Different types of fundal pigment disturbances 
are linked to vitiligo, such as pigment clumps, focal 
hypopigmented spots, diffuse hypopigmentation, 
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diffuse, focal, or sectoral atrophy of the RPE, or chorio-
retinal scars (42,46). Some researchers have observed 
ring-like peripapillary atrophy around the optic nerve 
(39). There are some isolated reports of vitiligo occur-
ring with tapetoretinal degeneration (47,48). Retinitis 
pigmentosa and retinitis pigmentosa-like syndromes 
are seen sporadically in patients with vitiligo, and 
patients with vitiligo more often complain of night 
blindness, but the relationship between vitiligo and 
retinitis pigmentosa is difficult to assess (42,46). 
Vitiligo is associated with many primarily autoim-
munologic disorders. Vitiligo is strongly associated 
with uveal inflammation in Vogt-Koyanagi-Harada 
disease, a systemic autoimmune disorder that affects 
pigmented tissues of the body, with the most severe 
manifestations in the eyes. Patients with Vogt-Koy-
anagi-Harada disease can present with early acute 
uveitic manifestations (i.e. bilateral diffuse choroiditis 
with bullous serous retinal detachment and optic disc 
hyperemia) and late ocular manifestations (i.e. diffuse 
fundus depigmentation, nummular depigmented 
scars, retinal pigment epithelium clumping and/or 
migration, and recurrent or chronic anterior uveitis), 
in addition to extraocular manifestations (neurolog-
ic/auditory and integumentary) (49). 
The connection between the anatomic localiza-
tion of vitiligo and ocular findings was primarily in-
vestigated by Rosenbaum et al. (50), who reported 
an association between bilateral changes in the RPE 
with periorbital vitiligo and seizures. Other research-
ers have come to similar conclusions. Wagoner et al. 
suggested that periocular skin depigmentation is a 
frequent abnormality in patients with ocular findings 
(44). Baskan et al. reported that ocular findings are 
primarily associated with periorbital and, to a lesser 
extent, genital vitiligo (39). 
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